Plasma aprotinin concentrations during cardiac surgery: Full- versus half-dose regimens

Anesthesia and Analgesia

Volumn 91, Issue 2, 2000, Pages 257-264

  Beath, Susan M ^a   Nuttall, Gregory A ^a,b   Fass, David N ^b   Oliver Jr , William C ^a   Ereth, Mark H ^a   Oyen, Lance J ^b  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ;

ADULT; ARTICLE; BLEEDING; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DETERMINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART SURGERY; HUMAN; MALE; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; WEIGHT;

EID: 0033861084     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/00000539-200008000-00002     Document Type: Article

References (25)

1. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery
2. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting
3. Aprotinin in primary valve replacement and reconstruction: A multicenter, double-blind, placebo-controlled trial
4. Clinical utility and cost effectiveness of aprotinin to reduce operative bleeding: Comparison with other antifibrinolytics
5. Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization
6. Effect of intraoperative aprotinin administration on postoperative bleeding in patients undergoing cardiopulmonary bypass operation
7. On the mechanism of platelet preservation during cardiopulmonary bypass by aprotinin
8. High-dose aprotinin therapy: A review of the first five years' experience
9. Aprotinin: A review of its pharmacology and therapeutic efficacy in reducing blood loss associated with cardiac surgery
10. Randomized placebo-controlled double-blind study of three aprotinin regimens in primary cardiac surgery
11. Influence of high- and low-dose aprotinin on activation of hemostasis in open-heart operations
12. Aprotinin: Safe and effective only with the full-dose regimen
13. Analyses of coronary graft patency after aprotinin use: Results from the international multicenter aprotinin graft patency experience (IMAGE) trial
14. Influence of high-dose aprotinin on anticoagulation, heparin requirement, and celite- and kaolin-activated clotting time in heparin-pretreated patients undergoing open-heart surgery: A double blind, placebo-controlled study
15. Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass
16. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol)
17. Maintenance of therapeutic plasma aprotinin levels during prolonged cardiopulmonary bypass using a large-dose regimen
18. Pharmacokinetics of aprotinin in preoperative cardiac surgical patients
19. The impact of renal dysfunction on aprotinin pharmacokinetics during cardiopulmonary bypass
20. Effects of 'low dose' aprotinin in open-heart surgery and its plasma concentration
21. Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs
22. Aprotinin reduces blood loss after cardiopulmonary bypass by direct inhibition of plasmin
23. Augmentation of kallikrein and plasmin inhibition capacity by aprotinin using a new assay to monitor therapy
24. Clinical application of inhibitors of fibrinolysis
25. The serine antiprotease aprotinin (Trasylol): A novel approach to reducing postoperative bleeding